ANIDULAFUNGIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C58H73N7O17
Molecular Weight	1140.2369
Optical Activity	UNSPECIFIED
Defined Stereocenters	15 / 15
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12C[C@@H](O)CN1C(=O)[C@@]([H])(NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@]3([H])[C@@H](O)[C@@H](C)CN3C(=O)[C@@]([H])(NC(=O)[C@@]([H])(NC2=O)[C@H](O)[C@@H](O)C4=CC=C(O)C=C4)[C@@H](C)O)NC(=O)C5=CC=C(C=C5)C6=CC=C(C=C6)C7=CC=C(OCCCCC)C=C7)[C@@H](C)O

InChI

InChIKey=JHVAMHSQVVQIOT-MFAJLEFUSA-N

InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C58H73N7O17
Molecular Weight	1140.2369
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	15 / 15
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf

Anidulafungin (brand names Eraxis (in U.S. and Russia) and Ecalta (in Europe)) is a semi-synthetic echinocandin with antifungal activity and it is active in vitro against many Candida, as well as some Aspergillus. Like other echinocandins, anidulafungin is not active against Cryptococcus neoformans, Trichosporon, Fusarium, or zygomycetes. This drug is indicated for the treatment of candidemia and the following Candida infections: intra-abdominal abscess and peritonitis; and for the treatment of esophageal candidiasis. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3--D-glucan, an essential component of the fungal cell wall.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
1,3-beta-glucan synthase 7 Target ID: CHEMBL2364673 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18473501	Inhibitor 8228

Conditions

Condition	Modality	Targets	Highest Phase	Product
Candidemia 3 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	Curative		Approved 8360	ERAXIS Approved Use ERAXIS is indicated for use in adults for the treatment of the following fungal infections listed below. Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies known. However, once these results become available, antifungal therapy should be adjusted accordingly. Anidulafungin is an echinocandin antifungal drug indicated in adults for the treatment of: Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) (1.1) Esophageal candidiasis (1.2) Limitations of use: has not been studied in endocarditis, osteomyelitis and meningitis due to Candida or in sufficient numbers of neutropenic patients (1.3) 1.1 Candidemia and Other Forms of Candida Infections (Intra-abdominal Abscess and Peritonitis) ERAXIS is indicated for the treatment of candidemia and the following Candida infections: intra-abdominal abscess and peritonitis [see Clinical Studies(14.1) and Clinical Pharmacology, Microbiology (12.4) Launch Date 1.14013438E12
Esophageal candidiasis 9 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	Curative		Approved 8360	ERAXIS Approved Use ERAXIS is indicated for use in adults for the treatment of the following fungal infections listed below. Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies known. However, once these results become available, antifungal therapy should be adjusted accordingly. Anidulafungin is an echinocandin antifungal drug indicated in adults for the treatment of: Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) (1.1) Esophageal candidiasis (1.2) Limitations of use: has not been studied in endocarditis, osteomyelitis and meningitis due to Candida or in sufficient numbers of neutropenic patients (1.3) 1.1 Candidemia and Other Forms of Candida Infections (Intra-abdominal Abscess and Peritonitis) ERAXIS is indicated for the treatment of candidemia and the following Candida infections: intra-abdominal abscess and peritonitis [see Clinical Studies(14.1) and Clinical Pharmacology, Microbiology (12.4) Launch Date 1.14013438E12

C_max

Value	Dose	Co-administered	Analyte	Population
7.2 mg/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	200 mg 1 times / day steady-state, intravenous dose: 200 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
4.2 mg/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	100 mg 1 times / day steady-state, intravenous dose: 100 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
110.3 mg × h/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	200 mg 1 times / day steady-state, intravenous dose: 200 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
55.2 mg × h/L DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	100 mg 1 times / day steady-state, intravenous dose: 100 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
26.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	200 mg 1 times / day steady-state, intravenous dose: 200 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
26.5 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	100 mg 1 times / day steady-state, intravenous dose: 100 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	200 mg 1 times / day steady-state, intravenous dose: 200 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf	100 mg 1 times / day steady-state, intravenous dose: 100 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		ANIDULAFUNGIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
200 mg 1 times / day multiple, intravenous Recommended Dose: 200 mg, 1 times / day Route: intravenous Route: multiple Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf Page: p.4	unhealthy, 16-89 n = 127 Health Status: unhealthy Condition: Candida infections\|Candidemia Age Group: 16-89 Sex: M+F Population Size: 127 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf Page: p.4	Disc. AE: Multi-organ failure... AEs leading to discontinuation/dose reduction: Multi-organ failure Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf Page: p.4
200 mg 1 times / day multiple, intravenous Recommended Dose: 200 mg, 1 times / day Route: intravenous Route: multiple Dose: 200 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/23676114 Page: p.4	unhealthy, 56.5 (± 18.5) n = 43 Health Status: unhealthy Condition: Candidemia Age Group: 56.5 (± 18.5) Sex: M+F Population Size: 43 Sources: https://pubmed.ncbi.nlm.nih.gov/23676114 Page: p.4	Disc. AE: Drug hypersensitivity, Skin rash... AEs leading to discontinuation/dose reduction: Drug hypersensitivity (2.3%) Skin rash (2.3%) Sources: https://pubmed.ncbi.nlm.nih.gov/23676114 Page: p.4
400 mg single, intravenous Overdose Dose: 400 mg Route: intravenous Route: single Dose: 400 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf Page: p.9	unhealthy Health Status: unhealthy Condition: Candida infections\|Candidemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf Page: p.9	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf Page: p.9
200 mg 1 times / day multiple, intravenous Recommended Dose: 200 mg, 1 times / day Route: intravenous Route: multiple Dose: 200 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Candida infections\|Candidemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf Page: p.1	Disc. AE: Abnormal liver function tests, Hepatitis... AEs leading to discontinuation/dose reduction: Abnormal liver function tests Hepatitis Hepatic failure Hypersensitivity Anaphylaxis Rash Urticaria Flushing Pruritus Bronchospasm Dyspnea Hypotension Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021632s011lbl.pdf Page: p.1

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1579	inhibitor 1752	inhibitor 1837

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP 110 CYP1A2 1509 CYP2A6 704 CYP2C19 1463 CYP2E1 876 P-gp 1437 BCRP 691	P-gp 1527 CYP 266	CYP 76

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
P-gp 1626	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 54.0	inconclusive
CYP 146	inducer 1542 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 54.0	no
CYP 146	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 54.0	no
CYP2E1 964	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no
CYP1A2 1673	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no	no (co-administration study) Comment: rifampin did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0
CYP2A6 736	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no	no (co-administration study) Comment: rifampin did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0
CYP2C19 1537	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no	no (co-administration study) Comment: voriconazole did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0
CYP2C9 1803	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no	no (co-administration study) Comment: voriconazole did not significantly alter anidulafungin pharmacokinetics; rifampin did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0
CYP2D6 1875	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no	no (co-administration study) Comment: rifampin did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0
CYP3A4 1909	inhibitor 3240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0	no	no (co-administration study) Comment: cyclosporine did not significantly alter anidulafungin pharmacokinetics; voriconazole did not significantly alter anidulafungin pharmacokinetics; rifampin did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44.0
BCRP 765	inhibitor 3240 Sources: https://pubmed.ncbi.nlm.nih.gov/27001813/	strong [IC50 7 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1527	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 54.0	inconclusive
CYP 266	substrate 3326 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44, 54	no		no (co-administration study) Comment: rifampin did not significantly alter anidulafungin pharmacokinetics Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/21948s000_Eraxis_BioPharrmR.pdf Page: 44, 54

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:55346	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:55346
ChemicalBook	CB71120054	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB71120054
MolPort	MolPort-006-167-527	https://www.molport.com/shop/molecule-link/MolPort-006-167-527
eMolecules	36905381	https://www.emolecules.com/cgi-bin/more?vid=36905381

PubMed

Title	Date	PubMed
Clinical microbiology and infectious diseases. Management of fungal infections.	2001 Jul	15995924
Anidulafungin: review of a new echinocandin antifungal agent.	2004 Aug	15482216
Gateways to clinical trials.	2004 Dec	15672123
Initial results from a longitudinal international surveillance programme for anidulafungin (2003).	2004 Dec	15564286
Management of invasive mycoses in hematology patients: current approaches.	2004 Nov	15651177
Echinocandins: ask not what they can do for esophageal candidiasis--ask what studies of esophageal candidiasis can do for them.	2004 Sep 15	15472818
A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.	2004 Sep 15	15472806
Compatibility of anidulafungin with other drugs during simulated Y-site administration.	2005 Apr 15	15821277
Overview of transplant mycology.	2005 Apr 15	15821262
Echinocandins: role in antifungal therapy, 2005.	2005 Aug	16086652
Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.	2005 Dec	16291712
Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine.	2005 Feb	15647416
Gateways to clinical trials.	2005 Jul-Aug	16179960
Anidulafungin: a new echinocandin with a novel profile.	2005 Jun	16117974
Antifungal agents in children.	2005 Jun	15925667
Gateways to clinical trials.	2005 May	16082427
New antifungal drugs and the pediatric cancer patient: current status of clinical development.	2005 May-Jun	15858708
Advances in antifungal therapy.	2005 Oct	16220093
Acquisitions not a cure for anti-infectives.	2005 Sep	16178116
Management of systemic fungal infections: alternatives to itraconazole.	2005 Sep	16120633
Echinocandin antifungals: review and update.	2006 Apr	16597212
In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species.	2006 Feb	16414247
Gateways to clinical trials.	2006 May	16801985
New drugs: lubiprostone, ranolazine, and anidulafungin.	2006 May-Jun	16739767
The safety of anidulafungin.	2006 Nov	17044802
Gateways to clinical trials.	2006 Sep	17003851
Echinocandins in the management of invasive fungal infections, part 1.	2006 Sep 15	16960253
Antifungal agents in neonates: issues and recommendations.	2007	17927303
Role of micafungin in the antifungal armamentarium.	2007	17504145
Fungal infections of the CNS: treatment strategies for the immunocompromised patient.	2007	17381184
Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment.	2007 Apr	17389555
One year prospective survey of Candida bloodstream infections in Scotland.	2007 Aug	17644714
[In vitro activity of amphotericin B and anidulafungin against Candida spp. biofilms].	2007 Dec 31	18095759
A comparative evaluation of properties and clinical efficacy of the echinocandins.	2007 Jul	17661730
Update on new antifungal therapy.	2007 Jul-Sep	18019516
Essential gene identification and drug target prioritization in Aspergillus fumigatus.	2007 Mar	17352532
Antifungal drug discovery, six new molecules patented after 10 years of feast: why do we need new patented drugs apart from new strategies?	2007 Nov	18221175
Mould breakthrough in immunosuppressed adults receiving anidulafungin: a report of 2 cases.	2007 Nov	17900699
Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients.	2007 Oct	17646966
Recent advances in antifungal agents.	2007 Sep	17897080
Susceptibility patterns of Candida species recovered from Canadian intensive care units.	2007 Sep	17869976
Anidulafungin and fluconazole for candidiasis.	2007 Sep 27	17902202
Anidulafungin and fluconazole for candidiasis.	2007 Sep 27	17898107
Advances in antifungal therapy.	2008	17967129
In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.	2008 Aug	18458136
Management of Candida infections in the adult intensive care unit.	2008 Feb	18201143
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.	2008 Feb	18070979
Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis.	2008 Feb	18057972
Anidulafungin was noninferior to fluconazole for invasive candidiasis.	2008 Jan-Feb	18171002
[Anidulafungin in the invasive fungal infection: current topics].	2008 Jun	18473499

Patents

Sample Use Guides

In Vivo Use Guide

Candidemia and other Candida infections (intra-abdominal abscess, and peritonitis) The recommended dose is a single 200 mg loading dose on Day 1, followed by 100 mg daily dose thereafter. Duration of treatment should be based on the patient’s clinical response. In general, antifungal therapy should continue for at least 14 days after the last positive culture. Esophageal Candidiasis: The recommended dose is a single 100 mg loading dose on Day 1, followed by 50 mg daily dose thereafter. Patients should be treated for a minimum of 14 days and for at least 7 days following resolution of symptoms. Duration of treatment should be based on the patient’s clinical response. Because of the risk of relapse of esophageal candidiasis in patients with HIV infections, suppressive antifungal therapy may be considered after a course of treatment.

Route of Administration: Intravenous

In Vitro Use Guide

A 48 hours exposure of human erythrocytes to Anidulafungin (1.5 - 6 µg/ml) significantly increased hemolysis and the percentage of annexin-V-binding cells, and significantly decreased forward scatter. Anidulafungin (6 µg/ml) slightly, but significantly inceased Fluo3-fluorescence and the effect of Anidulafungin on annexin-V-binding was slightly, but significantly blunted by removal of extracellular Ca2+. The effect of Anidulafungin on annexin-V-binding was further significantly blunted by the p38 kinase inhibitor SB203580 (2 µM) and NO donor nitroprusside (1 µM). An increase of extracellular K+ concentration significantly blunted the effect of Anidulafungin on cell volume but not on annexin-V-binding.

Substance Class	Chemical Created by `admin` on `Wed Jul 05 23:44:30 UTC 2023` Edited by `admin` on `Wed Jul 05 23:44:30 UTC 2023`
Record UNII	9HLM53094I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ANIDULAFUNGIN

Official Name

English

VER002

Code

English

LY-303366

Code

English

ANIDULAFUNGIN [ORANGE BOOK]

Common Name

English

Anidulafungin [WHO-DD]

Common Name

English

D70013

Code

English

ANIDULAFUNGIN [VANDF]

Common Name

English

LY303366

Code

English

ERAXIS

Brand Name

English

ANIDULAFUNGIN [USAN]

Common Name

English

ECHINOCANDIN B, 1-((4R,5R)-4,5-DIHYDROXY-N(SUP 2)-((4''-(PENTYLOXY)(1,1':4',1''-TERPHENYL)-4-YL)CARBONYL)-L-ORNITHINE)-

Common Name

English

V-ECHINOCANDIN

Common Name

English

(4R,5R)-4,5-DIHYDROXY-N(SUP 2)-((4''-(PENTYLOXY)-P-TERPHENYL-4-YL)CARBONYL)-L-ORNITHYL-L-THREONYL-TRANS-4-HYDROXY-L-PROLYL-(S)-4-HYDROXY-4-(P-HYDROXYPHENYL)-L-THREONYL-L-THREONYL-(3S,4S)-3-HYDROXY-4-METHYL-L-PROLINE CYCLIC (6->1)-PEPTIDE

Common Name

English

VER-002

Code

English

ANIDULAFUNGIN [MART.]

Common Name

English

ANIDULAFUNGIN [EMA EPAR]

Common Name

English

D-70013

Code

English

anidulafungin [INN]

Common Name

English

ANIDULAFUNGIN [MI]

Common Name

English

Classification Tree Code System Code

LIVERTOX

58